From NLO perspective:

NLO is one of Europe’s leading Intellectual Property consultancies, advising multinationals, SMEs, universities, R&D and governmental organisations. For over 135 years, we have protected and strengthened our clients’ innovations, ideas and trademarks with a strong focus on their markets. We offer a broad range of IP services, supported by over 60 patent and 20 trademark attorneys across offices in The Hague, Amsterdam, Ede and Eindhoven.

In March 2025 NLO entered a strategic partnership with Ipsilon, a full-service IP firm based in Paris. Together, we form a team of over 400 professionals, delivering integrated IP expertise across all major technical fields and regions.

Our Pharma and Life Sciences teams bring together patent attorneys with backgrounds in pharmaceutical R&D, biotechnology and the pharmaceutical industry. Their expertise spans drug repurposing, second medical use patents, SPCs, EPO oppositions, and innovations in antibodies, vaccines and gene therapies. Combined with their IP experience, our experts can advise pharmaceutical and biotechnology companies on patent protection, portfolio management and strategic IP matters throughout the innovation lifecycle.

From a group level perspective:

NLO | IPSILON brings together leading intellectual property expertise across the Netherlands, France and Belgium. With a combined team of over 400 professionals, including experienced patent and trademark attorneys, we advise multinationals, SMEs, universities, R&D institutions and governmental organisations on protecting and strengthening their innovations, ideas and brands.

Building on NLO's 135-year experience and IPSILON's strong European presence, our group delivers integrated IP services across all major technical fields and markets.

Our dedicated Pharma and Life Sciences teams combine scientific backgrounds with extensive experience in pharmaceutical R&D, biotechnology and the pharmaceutical industry. Their expertise covers drug repurposing, second medical use patents, supplementary protection certificates (SPCs), EPO oppositions, and innovations in antibodies, vaccines and gene therapies. Together, we support pharmaceutical and biotechnology companies with patent protection, portfolio management and strategic IP advice throughout the innovation lifecycle.

Venner Shipley is a leading European full-service intellectual property firm that advises on the entire lifecycle of intellectual property rights (IPR). The firm’s expertise spans the full range of IPR, including patents, trade marks, designs, and copyright, with particular strength in patent opposition proceedings at the European Patent Office (EPO). Venner Shipley’s IP professionals have extensive experience in patent prosecution, freedom to operate (FTO) analyses, IP strategy, due diligence, portfolio management, licensing, and other transactional services, and they represent clients before the UK IPO, the EPO, the EUIPO, and the IB of WIPO. Working in combination with the firm’s litigators, Venner Shipley offers a formidable, holistic, and strategic approach to resolving disputes.

With a combined headcount of more than 230 people, including 50 partners, Venner Shipley now operates across seven UK offices, in London, Bristol, Cambridge, Guildford, Manchester, Tunbridge Wells and Oxford, as well as EU offices in Munich and Alicante.

Venner Shipley advises on dispute resolution in the pharma sector, including matters relating to the regulation of metabolic processes, protein-based vaccines, small molecules, and medical devices. The firm also acts for generic pharmaceutical companies, defending against allegations of patent infringement and clearing the way for product launch. With offices in London and the EU, Venner Shipley coordinates global proceedings and can represent clients before the English Courts as well as Europe’s Unified Patent Court (the “UPC”). For further information, please visit: https://www.vennershipley.com/sectors/pharmaceuticals/

Hyman, Phelps & McNamara. P.C. has its finger on the pulse of the FDA and extensive experience with the universe of issues faced by companies regulated by FDA. As the largest dedicated FDA law firm in the United States, our technical expertise and industry knowledge are exceptionally wide and deep. Our nuanced understanding of the FDA’s inner workings helps you:

• Create efficient and effective strategies for premarket submissions and product approval
• Develop and execute regulatory and product lifecycle management strategies
• Establish and maintain high-quality, compliant processes and procedures for manufacturing, storage, and distribution
• Market compliant products
• Successfully promote products while meeting regulatory obligations
• Conduct internal audits and investigations
• Respond to government inspections and investigations
• Assess compliance and other regulatory issues (due diligence) for mergers and acquisitions.

Company’s website link: https://hpm.com/

From NLO perspective:

NLO is one of Europe’s leading Intellectual Property consultancies, advising multinationals, SMEs, universities, R&D and governmental organisations. For over 135 years, we have protected and strengthened our clients’ innovations, ideas and trademarks with a strong focus on their markets. We offer a broad range of IP services, supported by over 60 patent and 20 trademark attorneys across offices in The Hague, Amsterdam, Ede and Eindhoven.

In March 2025 NLO entered a strategic partnership with Ipsilon, a full-service IP firm based in Paris. Together, we form a team of over 400 professionals, delivering integrated IP expertise across all major technical fields and regions.

Our Pharma and Life Sciences teams bring together patent attorneys with backgrounds in pharmaceutical R&D, biotechnology and the pharmaceutical industry. Their expertise spans drug repurposing, second medical use patents, SPCs, EPO oppositions, and innovations in antibodies, vaccines and gene therapies. Combined with their IP experience, our experts can advise pharmaceutical and biotechnology companies on patent protection, portfolio management and strategic IP matters throughout the innovation lifecycle.

From a group level perspective:

NLO | IPSILON brings together leading intellectual property expertise across the Netherlands, France and Belgium. With a combined team of over 400 professionals, including experienced patent and trademark attorneys, we advise multinationals, SMEs, universities, R&D institutions and governmental organisations on protecting and strengthening their innovations, ideas and brands.

Building on NLO's 135-year experience and IPSILON's strong European presence, our group delivers integrated IP services across all major technical fields and markets.

Our dedicated Pharma and Life Sciences teams combine scientific backgrounds with extensive experience in pharmaceutical R&D, biotechnology and the pharmaceutical industry. Their expertise covers drug repurposing, second medical use patents, supplementary protection certificates (SPCs), EPO oppositions, and innovations in antibodies, vaccines and gene therapies. Together, we support pharmaceutical and biotechnology companies with patent protection, portfolio management and strategic IP advice throughout the innovation lifecycle.